← Back to Analyst Consensus 
FDMT Buy
4D Molecular Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 3 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 6, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Sep 29, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Sep 14, 2026 | Cantor Fitzgerald | upgrade | Neutral → Overweight | — | 50% |
| Jul 31, 2026 | B. Riley Securities | initiate | — → Buy | — | 55% |
| Jul 20, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 20, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 19, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Mar 19, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Jan 28, 2026 | Barclays | initiate | — → Overweight | $33 | 53% |
| Dec 18, 2025 | Chardan Capital | maintain | Buy → Buy | $26 | 47% |
| Nov 11, 2025 | RBC Capital | maintain | Outperform → Outperform | $32 | 55% |
| Nov 11, 2025 | Barclays | maintain | Overweight → Overweight | $33 | 53% |
| Nov 11, 2025 | Chardan Capital | maintain | Buy → Buy | $26 | 47% |
| Oct 21, 2025 | RBC Capital | reiterate | Outperform → Outperform | $26 | 55% |
| Aug 12, 2025 | Roth Capital | maintain | Buy → Buy | $38 | 53% |
| Aug 12, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Aug 1, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Jul 3, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| May 9, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| May 9, 2025 | Goldman Sachs | maintain | Buy → Buy | $44 | 54% |
| May 9, 2025 | Barclays | maintain | Overweight → Overweight | $38 | 53% |
| Mar 10, 2025 | B of A Securities | maintain | Buy → Buy | $40 | 53% |
| Mar 4, 2025 | Chardan Capital | maintain | Buy → Buy | $28 | 47% |
| Mar 3, 2025 | RBC Capital | maintain | Outperform → Outperform | $35 | 55% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Feb 11, 2025 | Chardan Capital | maintain | Buy → Buy | $30 | 47% |
| Feb 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Jan 13, 2025 | Morgan Stanley | maintain | Underweight → Underweight | $6 | 54% |
| Jan 13, 2025 | Leerink Partners | maintain | Outperform → Outperform | $27 | 51% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Dec 18, 2024 | B of A Securities | maintain | Buy → Buy | $46 | 53% |
| Nov 21, 2024 | Morgan Stanley | initiate | — → Underweight | $8 | 54% |
| Nov 14, 2024 | Chardan Capital | maintain | Buy → Buy | $39 | 47% |
| Nov 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Nov 14, 2024 | RBC Capital | maintain | Outperform → Outperform | $39 | 55% |
| Sep 23, 2024 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $0 | 50% |
| Sep 19, 2024 | Chardan Capital | maintain | Buy → Buy | $39 | 47% |
| Sep 19, 2024 | Leerink Partners | reiterate | Outperform → Outperform | $36 | 51% |
| Sep 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Aug 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Jul 22, 2024 | RBC Capital | reiterate | Outperform → Outperform | $40 | 55% |
| Jul 18, 2024 | BMO Capital | maintain | Outperform → Outperform | $40 | 53% |
| Jul 17, 2024 | Chardan Capital | maintain | Buy → Buy | $38 | 47% |
| Jun 26, 2024 | RBC Capital | reiterate | Outperform → Outperform | $40 | 55% |
| Jun 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| May 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Apr 15, 2024 | RBC Capital | maintain | Outperform → Outperform | $40 | 55% |
| Apr 15, 2024 | Barclays | initiate | — → Overweight | $45 | 53% |
Price Target Trend
Apr 26, 2026 Latest: $28.09 Oct 24, 2026
EPS Estimates
+1y $-4.09
Lo: $-4.94 Hi: $-3.38
10 analysts 0y $-4.15
Lo: $-4.30 Hi: $-4.00
11 analysts 0q $-1.05
Lo: $-1.10 Hi: $-0.99
11 analysts +1q $-1.06
Lo: $-1.23 Hi: $-0.95
11 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days